• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

    3/13/25 4:05:00 PM ET
    $ABT
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABT alert in real time by email

    Recent Collaboration Agreement with Abbott Global Enterprises Limited ("Abbott") in support of Phase 3 randomized, multicenter study, entitled TECH-LVAD

    Recent FDA Type D Meeting provides additional guidance for advancing clinical development of tecarfarin

    Leadership appointments to strengthen development capabilities

    Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company focused on the development of tecarfarin, a new Phase 3 ready oral vitamin K antagonist, today reported full year results for the period ended December 31, 2024, and provided a business update and highlights of the path forward for the clinical advancement of tecarfarin.

    "2024 for Cadrenal was a year of focus and laying the foundations for advancing tecarfarin into Phase 3 clinical development. With our eyes squarely centered on unmet needs in anticoagulation therapy, we have made strong progress on the partnering, regulatory, and financing fronts," said Quang X. Pham, Chairman & CEO. "Throughout 2025, our primary focus is on execution, as we move forward to assessing the efficacy and safety of tecarfarin in patients with left ventricular assist devices (LVAD) and consider other important areas of unmet need that a more reliable vitamin K antagonist could address."

    Full Year 2024 Key Accomplishments and Recent Highlights

    Collaboration Agreement with Abbott

    On March 4, 2025, we announced a Collaboration Agreement with Abbott (NYSE:ABT) to support Cadrenal's pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial. Under the agreement, Abbott will share insights from recent HeartMate 3™ clinical trials and will support Cadrenal with trial design, site identification, trial awareness, and HeartMate 3™ expertise.

    TECH-LVAD Trial Update

    On February 3, 2025, the Company had a Type D meeting with the U.S. Food and Drug Administration (FDA). The FDA provided additional guidance on the design of a future Phase 3 trial of tecarfarin and has requested the Company provide a full study design synopsis and detailed clinical trial design for review.

    Leadership Advances

    Cadrenal appointed James J. Ferguson, MD, FACC, FAHA, as Chief Medical Officer to lead the late-stage clinical development of tecarfarin and other indications in rare cardiovascular conditions requiring life-long anticoagulation therapy as well as other business development opportunities to build the Company's pipeline. Cadrenal also appointed Jeff Cole as Chief Operating Officer to oversee manufacturing, supply chain operations, intellectual property, and pre-commercialization strategies.

    Operational Milestones

    The Company and its pharmaceutical Contract Development and Manufacturing Organization (CDMO) completed necessary operational readiness activities to supply clinical trial materials for the upcoming tecarfarin pivotal Phase 3 trial in compliance with current Good Manufacturing Practices (cGMP). Cadrenal has also conducted market research in multiple indications, including LVAD, reinforcing Cadrenal's commitment to continuing pre-commercial work for tecarfarin.

    Strategic Development Collaborations

    Cadrenal continues to explore collaboration with potential development partners to advance tecarfarin's pivotal clinical trial for patients with LVAD and other rare cardiovascular conditions as well as other opportunities to advance the Company's clinical pipeline.

    Financial Growth and Fundraising Success

    During the year ended December 31, 2024, Cadrenal raised approximately $9.8 million in financing transactions, including $5.1 million through an at-the-market (ATM) facility and $4.7 million from warrant exercises.

    Industry Recognition and Engagement

    In October 2024, Cadrenal joined the Corporate Council of the Anticoagulation Forum (AC Forum). This association will enable the Company to collaborate with anticoagulation therapy thought leaders and 15,000 healthcare professionals to improve anticoagulation outcomes for patients globally. In November 2024, Cadrenal Therapeutics was named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook, an industry publication focused on breakthrough pharmaceutical technologies.

    Orphan Drug Designation for Tecarfarin

    In April 2024, Cadrenal received FDA Orphan Drug Designation (ODD) for tecarfarin to prevent thromboembolism in patients with implanted mechanical circulatory support devices, including LVADs, underscoring the investigational drug's potential impact on rare cardiovascular conditions. Tecarfarin already has ODD and Fast Track designation from the FDA for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib).

    Scientific Advocacy and Clinical Evidence

    The clinical need for tecarfarin was highlighted at the November 2024 European Association for Cardio-thoracic Surgery (EACTS) Mechanical Circulatory Support Summit in an address by Mandeep R. Mehra, MD, The William Harvey Distinguished Chair in Advanced Cardiovascular Medicine and Professor, Harvard Medical School. Dr. Mehra presented compelling data on the limitations of warfarin for LVAD patients and the potential of tecarfarin, if approved, to provide a safer alternative to these patients.

    Financial Results

    Research and development expenses for the year ended December 31, 2024, were $4.2 million compared to $4.1 million for the year ended December 31, 2023. General and administrative expenses for the year ended December 31, 2024, were $6.8 million compared to $3.5 million for the year ended December 31, 2023. Cadrenal reported a net loss of $10.7 million for the year ended December 31, 2024, compared to $8.4 million for the year ended December 31, 2023.

    Cadrenal's cash and cash equivalents totaled $10.0 million as of December 31, 2024, compared to $8.4 million as of December 31, 2023. The Company had approximately 1.8 million shares of common stock outstanding as of December 31, 2024.

    About Cadrenal Therapeutics, Inc.

    Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development of late-stage asset tecarfarin, a new oral vitamin K antagonist to address unmet needs in anticoagulation therapy. Tecarfarin is a late-stage, novel, oral, and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation. Although warfarin is widely used off-label for several rare cardiovascular conditions, extensive clinical and real-world data have shown it to have significant serious side effects. With its innovation, Cadrenal aims to meet the unmet needs of this patient population by relieving them and their healthcare providers of some of warfarin's greatest clinical challenges.

    Cadrenal is pursuing a product-in-a-pipeline approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including LVADs. The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib).

    Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus to build a pipeline of specialized cardiovascular therapeutics. For more information, visit www.cadrenal.com and connect with us on LinkedIn.

    Safe Harbor

    Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potentially," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding the Company's ability to assess the efficacy and safety of tecarfarin in patients with left ventricular assist devices (LVAD); Abbott supporting Cadrenal with trial design, site identification, trial awareness, and HeartMate 3™ expertise, including sharing insights from its HeartMate 3™ clinical trials; the late-stage clinical development of tecarfarin and other indications in rare cardiovascular conditions requiring life-long anticoagulation therapy as well as other business development opportunities to build the Company's pipeline; the Company continuing to explore collaborations with potential development partners to advance tecarfarin's pivotal clinical trial for patients with LVAD and other rare cardiovascular conditions as well as other opportunities; advancing the Company's clinical pipeline; the Company's association with the AC Forum enabling the Company to collaborate with anticoagulation therapy thought leaders and 15,000 healthcare professionals to improve anticoagulation outcomes for patients globally; the potential impact of tecarfarin on rare cardiovascular conditions; the potential of tecarfarin, if approved, to provide a safer alternative to LVAD patients; meeting the unmet needs of patients with rare cardiovascular conditions requiring chronic anticoagulation by relieving them and their healthcare providers of some of warfarin's greatest clinical challenges, and Cadrenal building a pipeline of specialized cardiovascular therapeutics. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to utilize Abbott's expertise to advance tecarfarin, the ability to successfully collaborate with Abbott, the initiation of the pivotal clinical trial for tecarfarin in LVAD patients by Cadrenal; for Cadrenal to provide improved patients outcomes and efficacy and safety for LVAD patients; the ability of Cadrenal to build a pipeline of specialized cardiovascular therapeutics and the other risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and the Company's subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

    (Tables to Follow)

    Cadrenal Therapeutics, Inc.
    Balance Sheets
     
     

    December 31, 2024

    December 31, 2023

    Assets:
    Current assets:
    Cash and cash equivalents $

    10,017,942

     

    $

    8,402,500

     

    Interest receivable

    38,153

     

    37,248

     

    Prepaid expenses and other current assets

    42,257

     

    52,425

     

    Deferred offering costs

    14,445

     

    -

     

    Total current assets

    10,112,797

     

    8,492,173

     

    Property, plant and equipment, net

    6,944

     

    2,287

     

    Right of use assets

    -

     

    20,998

     

    Other assets

    3,792

     

    3,792

     

    Total assets

    10,123,533

     

    8,519,250

     

    Liabilities and Stockholders' Equity:
    Current liabilities:
    Accounts payable $

    1,502,468

     

    $

    167,319

     

    Accrued liabilities

    1,181,490

     

    638,206

     

    Operating lease liability

    -

     

    21,350

     

    Total current liabilities

    2,683,958

     

    826,875

     

    Total liabilities

    2,683,958

     

    826,875

     

    Commitment and contingencies (Note 5)

    Stockholders' equity:
    Preferred stock, $0.001 par value, 7,500,000 shares authorized, no shares issued and outstanding at December 31, 2024 and December 31, 2023

    -

     

    -

     

    Common stock, $0.001 par value; 75,000,000 shares authorized, 1,782,486 shares issued and outstanding as of December 31, 2024; 868,184 shares issued and outstanding as of December 31, 2023 (1)

    1,782

     

    868

     

    Additional paid-in capital (1)

    33,160,576

     

    22,762,922

     

    Accumulated deficit

    (25,722,783

    )

    (15,071,415

    )

    Total stockholders' equity

    7,439,575

     

    7,692,375

     

    Total liabilities and stockholders' equity $

    10,123,533

     

    $

    8,519,250

     

     
    (1) All share and per share information has been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on August 20, 2024.
     
    CADRENAL THERAPEUTICS, INC.
    STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
     

    Years Ended

    December 31,

    2024

     

    2023

    Operating expenses:
    General and administrative expenses $

    6,753,726

     

    $

    3,549,514

     

    Research and development expenses

    4,205,013

     

    4,081,349

     

    Depreciation expense

    1,880

     

    1,980

     

    Total operating expenses

    10,960,619

     

    7,632,843

     

    Loss from operations

    (10,960,619

    )

    (7,632,843

    )

    Other (income) expense:
    Interest and dividend income

    (309,251

    )

    (249,092

    )

    Interest expense

    -

     

    3,534

     

    Interest expense, amortization of debt discount

    -

     

    13,567

     

    Change in fair value of derivative liabilities

    -

     

    216,095

     

    Loss on extinguishment of debt

    -

     

    740,139

     

    Total other (income) expense

    (309,251

    )

    724,243

     

    Net loss and comprehensive loss $

    (10,651,368

    )

    $

    (8,357,086

    )

     
    Net loss per common share, basic and diluted (1) $

    (8.73

    )

    $

    (9.29

    )

    Weighted average number of common shares used in computing net loss per common share, basic and diluted (1)

    1,219,550

     

    899,465

     

     
    (1) All share and per share information has been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on August 20, 2024.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250313043048/en/

    Corporate and Investor Relations

    Lisa DeScenza

    LaVoieHealthScience

    (978) 395-5970

    [email protected]



    Media

    Andrew Korda

    LaVoieHealthScience

    (617) 865-0043

    [email protected]

    Get the next $ABT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABT
    $CVKD

    CompanyDatePrice TargetRatingAnalyst
    Abbott Laboratories
    $ABT
    6/16/2025$143.00Market Perform
    Leerink Partners
    Abbott Laboratories
    $ABT
    10/8/2024$130.00Outperform
    Oppenheimer
    Abbott Laboratories
    $ABT
    9/19/2024$131.00Overweight
    Piper Sandler
    Abbott Laboratories
    $ABT
    7/30/2024Buy → Hold
    Edward Jones
    Abbott Laboratories
    $ABT
    5/30/2024$121.00Buy
    Goldman
    Cadrenal Therapeutics Inc.
    $CVKD
    12/18/2023$4.00Outperform
    Noble Capital Markets
    Abbott Laboratories
    $ABT
    7/21/2023Underperform → Peer Perform
    Wolfe Research
    Abbott Laboratories
    $ABT
    5/30/2023$112.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ABT
    $CVKD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Abbott Hosts Conference Call for Second-Quarter Earnings

      ABBOTT PARK, Ill., June 26, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its second-quarter 2025 financial results on Thursday, July 17, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica

      6/26/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New Research on Abbott's Healthy Food Rx Program Shows 'Food is Medicine' Approach Helps People Living With Diabetes Eat Better and Feel Healthier

      Randomized, controlled clinical trial presented as a late-breaking poster at ADA's Scientific Sessions shows people participating in Abbott's Healthy Food Rx ate more vegetables and fruit, and reported significantly improved health status.Abbott's Healthy Food Rx community-focused "food is medicine" program provides home-delivered healthy food boxes and nutrition education in Stockton, Calif., where 60% of the population has diabetes or pre-diabetes.CHICAGO, June 20, 2025 /PRNewswire/ -- Late-breaking research presented at the American Diabetes Association's 85th Scientific Sessions showed that Abbott's (NYSE:ABT) Healthy Food Rx "food is medicine" program helped people living with diabetes

      6/20/25 7:30:00 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Receives Health Canada Authorization for Whole Blood Rapid Test to Help Assess Suspected Concussions

      The test, run on Abbott's portable i-STAT® Alinity® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), otherwise known as concussionThe test produces lab-quality results in 15 minutesClinicians can get a result at the patient's bedside, making the test accessible at urgent care clinics and healthcare settings outside of the hospital emergency roomThe test can be used to help evaluate patients up to 24 hours after injuryMISSISSAUGA, ON, June 16, 2025 /CNW/ -- Abbott (NYSE:ABT) announced today that Health Canada has approved the company's i-STAT TBI test cartridge for use with whole blood, helping clinicians to assess suspected concussio

      6/16/25 8:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    $CVKD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

      For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

      10/24/23 3:52:17 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    $CVKD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Blount Sally E. sold $337,116 worth of Common shares without par value (2,600 units at $129.66), decreasing direct ownership by 7% to 34,058 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      5/2/25 5:04:05 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Stratton John G was granted 1,635 units of Common shares without par value, increasing direct ownership by 9% to 19,033 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      4/29/25 6:30:29 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Starks Daniel J was granted 1,635 units of Common shares without par value, increasing direct ownership by 0.02% to 6,728,817 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      4/29/25 6:22:08 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    $CVKD
    SEC Filings

    See more
    • SEC Form 11-K filed by Abbott Laboratories

      11-K - ABBOTT LABORATORIES (0000001800) (Filer)

      6/20/25 4:05:52 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Abbott Laboratories

      SD - ABBOTT LABORATORIES (0000001800) (Filer)

      5/29/25 11:01:45 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

      5/8/25 4:05:33 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care